Discovering and developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and topical diseases that stem from dysbiosis.
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy.
MabTrix is a preclinical stage biopharmaceutical company aiming to develop an innovative, function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) as the initial indication
Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug.
Protekt Therapeutics is a biopharmaceutical company aiming to develop a drug for enhancing the long-term memory of those suffering from mild cognitive impairment (MCI)
XoNovo is a biopharmaceutical company developing proprietary small molecules for the treatment of neurodegenerative diseases